Frontlight ResearchEarly access
CompletedPhase 2
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
Key facts
- Who runs it
- Knoa Pharma LLC
- Where
- Baytown, Brooklyn, Columbus, and Houston, United StatesSee the 4 sitesAlso in 1 other country, 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 209 people enrolled
- Started
- 14 Oct 2024
- Ended
- 5 May 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Sunobinop
- Placebo to match sunobinop
- Record updated
- 5 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Male and female age ≥18 years
- Diagnosis of moderate or severe alcohol use disorder
- Currently seeking treatment for alcohol use disorder
- Has 4 or more heavy drinking days (HDD) in each of the 4 weeks prior to baseline visit
Who cannot take part
- Subjects that meet current DSM-5 criteria for moderate or severe substance use disorder other than alcohol and nicotine; Other protocol-specific inclusion and exclusion criteria may apply
Where in United States
Also in 1 other country, 3 sites
- Inquest Clinical ResearchBaytown, United States
- Belmont Medical OfficeBrooklyn, United States
- Ohio Clinical TrialsColumbus, United States
- Cebis Usa, LlcHouston, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
The 2 groups in the trial
- SunobinopTreatment being tested
- Placebo to match sunobinopPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
- Record updated
- 5 June 2026